The use of colistin in multidrug-resistant infections

Hospital Pharmacy

Volumn 42, Issue 12, 2007, Pages 1127-1138

  Zapantis, Antonia ^a,b   Lopez, Mary ^c   Hoffman, Emily ^a   Lopez, Angelica ^c   Hamilton, Grace ^d  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Broward General Medical Center   (United States)

^c Broward General Medical Center ^*

^d FLORIDA HOSPITAL   (United States)

Author keywords

Colistin; MDR; Multidrug resistance; Polymyxins

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; MONOBACTAM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ALBUMINURIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG STRUCTURE; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PNEUMONIA; POLYNEUROPATHY; PRURITUS; PSEUDOMONAS AERUGINOSA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; URINE VOLUME; URTICARIA;

EID: 39449095793     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4212-1127     Document Type: Review

References (33)

1. Rybak MJ. Resistance to antimicrobial agents: an update. Pharmacotherapy. 2004;24(12 pt 2):203S-215S.
2. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33(9):960-967.
3. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January through June 1992, issued August 2003. Am J Infect Control. 2003;31(8):481-498.
4. Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med. 2006;70(1):25-28.
5. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(suppl 2):S100-S105.
6. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003;17(3):545-562.
7. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
8. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis. 2005;5(1):24.
9. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas Aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25(10):1353-1364.
10. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006;12(4):315-321.
11. Coly-Mycin M [package insert]. Rochester, MI: Monarch; 2006.
12. Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect Dis Clin North Am. 2004;18;669-689.
13. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333-1341.
14. Li J, Nation RL, Milne RW, Turnridge JD, Coulthard K. Evaluation of colistin as an agent against multiresistant gram negative bacteria. Int J Antimicrob Agents. 2005;25:11-25.
15. Scheetz MH, Hurt KH, Noskin GA, Oliphant CM. Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am J Health Syst Pharm. 2006;63:1346-1360.
16. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001;39(1):183-190.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. 2006. Wayne, PA.
18. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003;47(5):1681-1688.
19. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004;38:1449-1459.
20. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000;31(3):690-697.
21. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care. 2003:7(5):R78-R83. http://ccforum.com/content/7/5/ R78. Accessed October 10, 2007.
22. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-1011.
23. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154-e160.
24. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-1118.
25. Berlana B, Llop JM, Fort E, Badian MB, Jódar R. Use of colistin in the treatment of multiple-drug resistant gram-negative infections. Am J Health Syst Pharm. 2005;62:39-47.
26. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelpoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infection caused by multi-resistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11(2)115-121.
27. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5(1):1.
28. Karabinis A, Paramythiotou E, Mylona-Petropoulou D, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis. 2004:38:e7-e9.
29. Food and Drug Administration. MedWatch Adverse Event Reporting System (March 2004 to December 2006). http://www.fda.gov/cder/aersextract.htm. Accessed April 3, 2007.
30. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother. 2006;50(6):2274-2275.
31. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol. 2002;34(4):257-261.
32. Thiolas A, Bollet C, La Scola B, Raoult D Pagés JM. Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrobial Agents and Chemotherapy. 2005:49(4):1354-1358.
33. Institute for Safe Medication Practices. ISMP's list of error-prone abbreviations, symbols, and dose designations. http://www.ismp.org/Tools/ errorproneabbreviations.pdf. Accessed April 1, 2007.